Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts
- PMID: 2354443
Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts
Abstract
Using preclinical models of human colon adenocarcinomas in immune-deprived mice, the influence of dose of [6RS]leucovorin ([6RS]LV, 20 to 1000 mg/m2) administered by 24-h i.v. infusion was determined on the following parameters: (a) plasma concentrations of the active [6S] and inactive [6R] isomers of [6RS]LV and the biologically active diastereoisomer of 5-methyltetrahydrolate (5-CH3-H4PteGlu); (b) expansion of intratumor pools of 5,10-methylenetetrahydrofolates (CH2-H4PteGlun) and tetrahydrofolates (H4PteGlun), that may influence the binding of 5-fluorodeoxyuridylate to thymidylate synthase; (c) the distribution of polyglutamate forms of CH2-H4PteGlun and H4PteGlun; and (d) (5-fluorouracil (FUra)-mediated thymidylate synthase inhibition in Hx-ELC2, HxGC3, HxVRC5, and HxHC1 tumors. Folypolyglutamate synthetase activities were also determined in each line. Linear increases in plasma concentrations of [6R]LV, [6S]LV, and 5-CH3-H4-PteGlu were determined over the complete range of [6RS]LV doses examined. However, in neoplastic tissues three patterns of biochemical modulation by [6RS]LV were evident. (a) In HxELC2 and HxVRC5 tumors, pools of CH2-H4PteGlun and H4PteGlun were elevated in proportion to the dose of [6RS]LV between dose levels of 50 and 200 mg/m2. Subsequent expansion of these pools continued that was disproportionate to the dose of [6RS]LV until no further increase was observed beyond 800 mg/m2 [6RS]LV, at which point pools were maximally expanded by 4- to 4.5-fold. The extent of retardation of recovery of thymidylate synthase activity increased as the dose of [6RS]LV was increased in both tumors, when FUra (15 or 50 mg/kg), was administered by i.v. bolus injection 3 h into the 24-h infusion of [6RS]LV. This was related to the increase in predominance of CH2-H4PteGlu2-5 with increasing dose of [6RS]LV. (b) For HxHC1 tumors, little expansion of CH2-H4PteGlun and H4PteGlun pools (maximum, 137% of control) was detected at the highest dose levels of [6RS]LV, and no significant modulation of FUra-inhibited thymidylate synthase activity was detected, even at 1000 mg/m2 [6RS] LV. CH2-H4PteGlu5 remained similar or decreased as the dose of [6RS] LV was increased. (c) For line HxGC3, pools of CH2-H4PteGlun and H4PteGlun increased gradually from 169% of control at 20 mg/m2 [6RS] LV to 233% of control at 1000 mg/m2 [6RS]LV, and were intermediate between the expansion observed in HxHC1 in comparison to HxELC2 and HxVRC5 tumors. CH2-H4PteGlu3-5 were elevated at low dose levels of [6RS]LV.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Relationship between dose rate of [6RS]Leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts.Cancer Res. 1990 Jun 15;50(12):3493-502. Cancer Res. 1990. PMID: 2140289
-
Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts.Cancer Chemother Pharmacol. 1992;30(6):423-32. doi: 10.1007/BF00685592. Cancer Chemother Pharmacol. 1992. PMID: 1394798
-
Characterization of the pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in xenografts of human colon adenocarcinoma.Cancer Res. 1988 Jun 1;48(11):3062-9. Cancer Res. 1988. PMID: 3365696
-
[Biochemical modulation of 5-fluorouracil by high-dose leucovorin].Gan To Kagaku Ryoho. 1988 Mar;15(3):392-408. Gan To Kagaku Ryoho. 1988. PMID: 3279911 Review. Japanese.
-
Leucovorin modulation of fluorouracil.Oncology (Williston Park). 1993 Aug;7(8):63-72; discussion 75-6. Oncology (Williston Park). 1993. PMID: 8398636 Review.
Cited by
-
Intracellular metabolism of 5-methyltetrahydrofolate and 5-formyltetrahydrofolate in a human breast-cancer cell line.Cancer Chemother Pharmacol. 1994;34(6):491-6. doi: 10.1007/BF00685660. Cancer Chemother Pharmacol. 1994. PMID: 7522978
-
Pharmacologic modulation of 5-fluorouracil by folinic acid and high-dose pyridoxine for treatment of patients with digestive tract carcinomas.Sci Rep. 2021 Jun 16;11(1):12668. doi: 10.1038/s41598-021-92110-5. Sci Rep. 2021. PMID: 34135415 Free PMC article.
-
Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer.Br J Clin Pharmacol. 1994 Mar;37(3):243-8. doi: 10.1111/j.1365-2125.1994.tb04270.x. Br J Clin Pharmacol. 1994. PMID: 8198932 Free PMC article. Clinical Trial.
-
Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.Cancer Chemother Pharmacol. 1995;35(3):205-12. doi: 10.1007/BF00686549. Cancer Chemother Pharmacol. 1995. PMID: 7805178 Clinical Trial.
-
Pharmacologic modulation of 5-fluorouracil by folinic acid and pyridoxine for treatment of patients with advanced breast carcinoma.Sci Rep. 2022 May 31;12(1):9079. doi: 10.1038/s41598-022-12998-5. Sci Rep. 2022. PMID: 35641554 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources